MeiraGTx Shares Rise Premarket on Ophthalmology Collaboration With Eli Lilly
By Colin Kellaher
MeiraGTx Holdings shares rose sharply in premarket trading Monday after the clinical-stage genetic-medicines said it formed a ophthalmology collaboration potentially worth hundreds of millions of dollars with drugmaker Eli Lilly.
Shares of MeiraGTx, which closed Friday at $8.47, were recently up 15% to $9.74 in premarket trading.
MeiraGTx said it will receive an upfront payment of $75 million from Eli Lilly as part of the collaboration and will be eligible for more than $400 million in total milestone payments, along with royalties on licensed products.
The New York company said it will grant Eli Lilly worldwide exclusive rights to its AAV-AIPL1 program for treatment of one of the most severe inherited retinopathies and worldwide exclusive access rights to its gene-therapy technologies for use in ophthalmology with certain targets named by Lilly.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 10, 2025 08:33 ET (13:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
The 10 Best Companies to Invest in Now
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
3 Stocks to Invest In With More Room to Run
United States